Metabolic signatures linked to macrophage polarization: from glucose metabolism to oxidative phosphorylation.

Macrophages are present in a large variety of locations, playing distinct functions that are determined by its developmental origin and by the nature of the activators of the microenvironment. Macrophage activation can be classified as pro-inflammatory (M1 polarization) or anti-inflammatory-pro-resolution-deactivation (M2), these profiles coexisting in the course of the immune response and playing a relevant functional role in the onset of inflammation (Figure 1). Several groups have analysed the metabolic aspects associated with macrophage activation to answer the question about what changes in the regulation of energy metabolism and biosynthesis of anabolic precursors accompany the different types of polarization and to what extent they are necessary for the expression of the activation phenotypes. The interest of these studies is to regulate macrophage function by altering their metabolic activity in a 'therapeutic way'.

[1]  Z. Fayad,et al.  HIF-1&agr; and PFKFB3 Mediate a Tight Relationship Between Proinflammatory Activation and Anerobic Metabolism in Atherosclerotic Macrophages , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[2]  Steffen Jung,et al.  Macrophages: development and tissue specialization. , 2015, Annual review of immunology.

[3]  Susan R. Quinn,et al.  Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. , 2015, Cell metabolism.

[4]  Haichao Wang,et al.  PKM2 Regulates the Warburg Effect and Promotes HMGB1 Release in Sepsis , 2014, Nature Communications.

[5]  Zachary W. Dwyer,et al.  SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells. , 2014, Molecular cell.

[6]  L. Boscá,et al.  Involvement of monocytes/macrophages as key factors in the development and progression of cardiovascular diseases. , 2014, The Biochemical journal.

[7]  V. Fuster,et al.  2-deoxy-2-[18F]fluoro-d-mannose positron emission tomography imaging in atherosclerosis , 2014, Nature Medicine.

[8]  P. Taylor,et al.  Tissue-resident macrophages , 2013, Nature Immunology.

[9]  Jie Li,et al.  PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells , 2013, Cell.

[10]  P. Carmeliet,et al.  Role of PFKFB3-Driven Glycolysis in Vessel Sprouting , 2013, Cell.

[11]  P. Libby,et al.  Local proliferation dominates lesional macrophage accumulation in atherosclerosis , 2013, Nature Medicine.

[12]  W. Sellers,et al.  M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth , 2012, Proceedings of the National Academy of Sciences.

[13]  Eyal Gottlieb,et al.  Serine is a natural ligand and allosteric activator of pyruvate kinase M2 , 2012, Nature.

[14]  Christian M. Metallo,et al.  Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis , 2012, Nature chemical biology.

[15]  E. Gottlieb,et al.  Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. , 2012, Trends in biochemical sciences.

[16]  K. Venema,et al.  Propionic acid affects immune status and metabolism in adipose tissue from overweight subjects , 2012, European journal of clinical investigation.

[17]  M. Cascante,et al.  Relevance of the MEK/ERK Signaling Pathway in the Metabolism of Activated Macrophages: A Metabolomic Approach , 2012, The Journal of Immunology.

[18]  P. Libby,et al.  Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. , 2011, Journal of the American College of Cardiology.

[19]  Peter Carmeliet,et al.  Hypoxia and inflammation. , 2011, The New England journal of medicine.

[20]  Wei-Shou Hu,et al.  Glucose metabolism in mammalian cell culture: new insights for tweaking vintage pathways. , 2010, Trends in biotechnology.

[21]  Daniel Rico,et al.  Substrate Fate in Activated Macrophages: A Comparison between Innate, Classic, and Alternative Activation , 2010, The Journal of Immunology.

[22]  A. Mantovani,et al.  Molecular pathways linking inflammation and cancer. , 2010, Current molecular medicine.

[23]  S. Gordon,et al.  Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.

[24]  C. Glass,et al.  Macrophages, inflammation, and insulin resistance. , 2010, Annual review of physiology.

[25]  L. Boscá,et al.  Lipoxin A4 impairment of apoptotic signaling in macrophages: implication of the PI3K/Akt and the ERK/Nrf-2 defense pathways , 2010, Cell Death and Differentiation.

[26]  L. Pellerin,et al.  Enhanced Cerebral Expression of MCT1 and MCT2 in a Rat Ischemia Model Occurs in Activated Microglial Cells , 2009, Journal of Cerebral Blood Flow and Metabolism.

[27]  Vidya Subramanian,et al.  Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. , 2008, Cell metabolism.

[28]  John O Trent,et al.  Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth , 2008, Molecular Cancer Therapeutics.

[29]  S. Gordon The macrophage: Past, present and future , 2007, European journal of immunology.

[30]  V. Nizet,et al.  Cutting Edge: Essential Role of Hypoxia Inducible Factor-1α in Development of Lipopolysaccharide-Induced Sepsis1 , 2007, The Journal of Immunology.

[31]  Juan M. Vaquerizas,et al.  Identification of conserved domains in the promoter regions of nitric oxide synthase 2: implications for the species-specific transcription and evolutionary differences , 2007, BMC Genomics.

[32]  A. Lane,et al.  Ras transformation requires metabolic control by 6-phosphofructo-2-kinase , 2006, Oncogene.

[33]  Alberto Mantovani,et al.  Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 , 2006, The Journal of Immunology.

[34]  R. Bucala,et al.  Phosphorylation of the 6-Phosphofructo-2-Kinase/Fructose 2,6-Bisphosphatase/PFKFB3 Family of Glycolytic Regulators in Human Cancer , 2005, Clinical Cancer Research.

[35]  L. Boscá,et al.  Nitric oxide and cell viability in inflammatory cells: a role for NO in macrophage function and fate. , 2005, Toxicology.

[36]  J. L. Rosa,et al.  6-Phosphofructo-2-kinase (pfkfb3) Gene Promoter Contains Hypoxia-inducible Factor-1 Binding Sites Necessary for Transactivation in Response to Hypoxia* , 2004, Journal of Biological Chemistry.

[37]  R. Sakakibara,et al.  Identification and characterization of the hypoxia-responsive element of the human placental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene. , 2004, Journal of biochemistry.

[38]  D. Vertommen,et al.  6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. , 2004, The Biochemical journal.

[39]  N. Sang,et al.  Hypoxia-inducible Factor-1-mediated Expression of the 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) Gene , 2002, The Journal of Biological Chemistry.

[40]  K. Uyeda,et al.  Regulation of Energy Metabolism in Macrophages during Hypoxia , 2001, The Journal of Biological Chemistry.

[41]  R. Gamelli,et al.  EXPRESSION OF THE LACTATE TRANSPORTER MCT1 IN MACROPHAGES , 2000, Shock.

[42]  P. Newsholme,et al.  Rates of utilization of glucose, glutamine and oleate and formation of end-products by mouse peritoneal macrophages in culture. , 1989, The Biochemical journal.

[43]  A. Sols,et al.  Modulation of muscle phosphofructokinase at physiological concentration of enzyme. , 1985, The Journal of biological chemistry.

[44]  Mitochondrial membrane-bound hexokinase of ascites tumor cells. Functional implications of lysine residues studied by modification with imidoesters. , 1982, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[45]  A. Sols,et al.  Substrate specificity of brain hexokinase. , 1954, The Journal of biological chemistry.